Discounted Cash Flow (DCF) Analysis Unlevered

PDS Biotechnology Corporation (PDSB)

$6.5501

-0.04 (-0.61%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 6.5501 | undervalue

Operating Data

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 6.5,501
Beta 1.727
Diluted Shares Outstanding 28.60
Cost of Debt
Tax Rate 2.85
After-tax Cost of Debt 5.45%
Risk-Free Rate
Market Risk Premium
Cost of Equity 12.366
Total Debt 23.47
Total Equity 187.33
Total Capital 210.80
Debt Weighting 11.14
Equity Weighting 88.86
Wacc

Build Up Free Cash

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 6.37%5.17%0.00%21.07%2.85%7.09%7.09%7.09%7.09%7.09%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure ----------
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 11.60
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -50.35
Equity Value -
Shares Outstanding 28.60
Equity Value Per Share -